This study tests a new treatment for high-risk myeloma, a type of blood cancer. The treatment uses three medicines: belantamab mafodotin, a special antibody that delivers chemotherapy to cancer cells; pomalidomide, a drug that stops cancer cells from growing; and dexamethasone, which reduces inflammation. This treatment aims to kill more cancer cells.
Participants will receive belantamab mafodotin through an IV once every two cycles (56 days), pomalidomide as a daily pill for 21 days each cycle (28 days), and dexamethasone as a pill on specific days. The study lasts until the cancer stops responding or side effects become too severe. Afterward, patients will have check-ups every 3 months.
- Length and Visits: Treatment cycles are 28 days, with regular follow-up visits.
- Eligibility: Patients must have recently undergone a stem cell transplant and meet specific health criteria.
- Risks: Possible side effects include eye problems, liver issues, or infections. Contact lenses are not allowed during the study.
How understandable was the trial content above?
Hard to understand
Easy to understand